bpc-157 regulatory status fda 2025 advisory committee votes to add popular peptide to drug compounding list FDA Peptide Reclassification 2026: What

Conclusion: Fifty years after its initial discovery, GHK-Cu continues to generate compelling research interest for a straightforward reason: no other single peptide compound has demonstrated comparable breadth of biological activity at such low concentrations

It interacts with glucagon receptors, gastric inhibitory peptide receptors, and glucagon-like peptide-1 receptors

But peptides remain difficult to deliver across oral mucosa

Even a really high oral dose of 1000 g would only deliver at most 13 g

In one study, subjects immediately reported feeling "sleep pressure" after DSIP administration, and total sleep time increased by 59% within 130 minutes compared to placebo